CDK Inhibitor R547 Attenuates Pressure Overload-Induced Cardiac Hypertrophy Through PI3K/AKT and TGF-β/Smad3...

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Pharmacology

Background:

• Chronic stress leads to cardiac hypertrophy, a precursor to heart failure.
• Current therapies for cardiac hypertrophy have limited mechanistic targeting.
• Cyclin-dependent kinases (CDKs) are key regulators of cell cycle and stress signaling in cardiovascular pathologies.

Purpose of the Study:

• To investigate the therapeutic effects of the CDK inhibitor R547 on pressure overload-induced cardiac remodeling.
• To explore the molecular mechanisms underlying R547's efficacy in a murine transverse aortic constriction (TAC) model and human data.

Main Methods:

• Bioinformatics analysis of human hypertrophic cardiomyopathy datasets (GSE5500, GSE136308).
• Utilized a murine TAC model to induce pressure overload.
• Assessed cardiac function via echocardiography and molecular mechanisms through proteomics and pathway analyses.

Main Results:

• CDKs were significantly upregulated in human heart failure and TAC mouse models.
• R547 treatment attenuated cardiac hypertrophy and fibrosis in TAC mice.
• R547 improved cardiac function, preserving ejection fraction and reducing ventricular wall thickening.

Conclusions:

• CDK-driven signaling is a central regulator of pressure overload cardiomyopathy.
• R547 demonstrates dual inhibition of PI3K/AKT/mTOR and TGF-β/Smad3 pathways.
• R547 shows promise as a multifactorial therapy for cardiac hypertrophy and heart failure.